Pagel, J. M., Soumerai, J. D., Reddy, N., Jagadeesh, D., Stathis, A., Asch, A., Salman, H., Kenkre, V. P., Iasonos, A., Llorin-Sangalang, J., Li, J., & Zelenetz, A. D. (2022). zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet oncology, 23(8), 1021–1030. http://access.bl.uk/ark:/81055/vdc_100159754268.0x00001d